Clinical Trials on Mild and Moderate Renal Impairment

Total 13408 results

Novartis Pharmaceuticals

Completed

Pharmacokinetic Study of Buparlisib in Subjects With Renal Impairment.

Renal Impairment

Czechia, Germany, Romania, Bulgaria
Spero Therapeutics

Completed

Phase 1 Study of PK and Safety of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Subjects With Various Degrees Of Renal Function

Renal Impairment

United States
Ipsen

Completed

Study to Compare a Dose of Telotristat Etiprate in Subjects With Renal Impairment With Matched Subjects With Normal Renal Function

Renal Impairment

Moldova, Republic of, Belgium, Germany, Romania
IlDong Pharmaceutical Co Ltd

Unknown

Pharmacokinetics of Besifovir in Adults With Normal and Impaired Renal Function

Renal Impairment
Eisai Inc.

Completed

Pharmacokinetic Properties of Lorcaserin in Subjects With Renal Impairment

Renal Impairment

United States
Merck KGaA, Darmstadt, Germany

Completed

Effect of Renal Impairment on Evobrutinib Pharmacokinetics (PK)

Renal Impairment

Germany
Guerbet

Terminated

Effects of Contrast Media on Subjects With Stable Reduced Renal Function Undergoing Contrast-Enhanced Computed Tomography (CINOPSIS CT)

Renal Impairment

United States
Merck Sharp & Dohme LLC

Completed

A Study Evaluating the Pharmacokinetics of Doravirine (MK-1439) in Participants With Severe Renal Impairment (MK-1439-051)

Renal Impairment
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics of Sugammadex (MK-8616) in Participants With Moderate and Severe Renal Insufficiency (MK-8616-105)

Renal Insufficiency | Renal Impairment

United States
ContraVir Pharmaceuticals, Inc.

Completed

Evaluation of Effect of Renal Impairment on the PK of Tenofovir Exalidex

Renal Impairment

United States
Pfizer

Completed

Study Of Palbociclib (PD-0332991) In Renal Impairment

Renal Impairment

United States
Global Blood Therapeutics

Completed

Single-Dose PK Study of GBT440 in Subjects With Renal Impairment

Renal Impairment

United States
PTC Therapeutics

Completed

A Single Dose Evaluation of the Effects of Renal Impairment on Deflazacort Pharmacokinetics

Renal Impairment

United States
Sahlgrenska University Hospital, Sweden

Completed

NAG-excretion During Cardiopulmonary Bypass (CPBNAG)

Renal Impairment

Sweden
Alkermes, Inc.

Completed

Pharmacokinetics and Safety of ALKS 5461 in Subjects With Renal Impairment and Normal Renal Function

Renal Impairment

United States
Cubist Pharmaceuticals LLC
Syneos Health

Terminated

Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment

Renal Impairment

United States
Toray Industries, Inc

Completed

A Pharmacokinetic Study of TRK-100STP in Japanese Patients With Renal Impairment

Renal Impairment

Japan
Nycomed
NPS Pharma

Completed

Pharmacokinetics of 10 mg Teduglutide in Subjects With Renal Impairment Compared to Healthy Subjects With Normal Renal Function

Renal Impairment

Germany
AstraZeneca

Completed

Study to Investigate the Effects of AZD6140 in Patients With Renal Impairment and in Healthy Volunteers

Renal Impairment

United States
VIVUS LLC

Completed

A Study to Evaluate the Pharmacokinetics of VI-0521 Subjects With Renal Impairment

Renal Impairment

United States
AstraZeneca

Completed

Safety Study of AZD5672 in Renally Impaired Subjects

Renal Impairment

Germany
Shionogi

Completed

A Study to Assess S-217622 in Participants With Renal Impairment and Healthy Participants

Renal Impairment

United States
Insmed Incorporated

Completed

A Study of Brensocatib Following a Single Oral Administration in Participants With or Without Renal Impairment

Renal Impairment

United States
Concert Pharmaceuticals

Completed

Study to Assess the Effect of Renal Impairment on the Pharmacokinetics of CTP-543

Renal Impairment

United States
Zogenix, Inc.

Completed

Pharmacokinetics and Metabolism of Hydrocodone Bitartrate Extended-Release (HC-ER) in Subjects With Renal Impairment

Renal Impairment
Sunshine Lake Pharma Co., Ltd.

Completed

Pharmacokinetics of Yimitasvir Phosphate Capsule in Subjects With Normal Renal Function and ESRD

Renal Impairment

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Renal Impairment

Renal Impairment

China
Pfizer

Completed

A Renal Impairment Study for PF-04965842

Renal Impairment

United States, Belgium
AstraZeneca

Completed

Study to Assess the Pharmacokinetics and Safety of AZD9977 in Participants With Renal Impairment

Renal Impairment

United States
Pfizer

Terminated

A Renal Impairment Study for PF-06651600

Renal Impairment

United States
Pfizer

Completed

Lorlatinib Renal Impairment Study

Renal Impairment

United States
Novartis Pharmaceuticals

Completed

A Phase l Study to Evaluate the Pharmacokinetics and Safety Pasireotide in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Volunteers

Renal Impairment

Germany, South Africa
Novartis Pharmaceuticals

Completed

Comparing the Pharmacokinetics, Safety and Tolerability of NVA237 in Renal Impairment

Renal Impairment

Russian Federation
Novartis Pharmaceuticals

Completed

A Phase I Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Renal Function

Renal Impairment

Germany, Bulgaria
Zealand Pharma

Completed

Pharmacokinetic Profile of Glepaglutide After a Single Injection in Subjects With Varying Degrees of Renal Function

Renal Impairment

Hungary, Poland
Eisai Inc.
Purdue Pharma LP

Completed

Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Normal Renal Function or With Severe Renal Impairment

Renal Impairment

United States
Mallinckrodt

Terminated

Pharmacokinetic Assessment of Sodium Sulfide in Subjects With Impaired Renal Function

Renal Impairment

United States
Pfizer

Completed

Glasdegib Renal Impairment Study

Renal Impairment

United States
H. Lundbeck A/S

Completed

Pharmacokinetic Properties of Nalmefene in Subjects With Renal Impairment and in Healthy Subjects

Renal Impairment

Germany
Trius Therapeutics LLC

Completed

A Pharmacokinetics and Safety Study in Subjects With Renal Impairment

Renal Impairment

United States
Dong-A ST Co., Ltd.

Completed

PK//PD/Tolerability Study of DA-1229(Evogliptin) in Renal Impaired Patients

Renal Impairment

Korea, Republic of
Sahlgrenska University Hospital, Sweden

Completed

Fluid Investigation Colloid vs Crystalloid Reg. Renal Hemodynamics and Function

Renal Impairment

Sweden
Sanofi

Completed

Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal Impairment

Renal Impairment

United States
AstraZeneca

Completed

Assessing the Pharmacokinetics of NKTR-118 in Subjects With Renal Impairment Compared to That in Subjects With Normal Renal Function

Renal Impairment

United States
Repros Therapeutics Inc.

Terminated

Evaluate PK and Safety of Proellex® in Females With Various Stages of Impaired Renal Function and Healthy Females

Renal Impairment

United States
Galapagos NV

Completed

Study to Evaluate GLPG0634 in Subjects With Renal Impairment Compared to Healthy Subjects

Renal Impairment

Germany
Sanofi

Completed

Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild, Moderate and Severe Renal Impairment

Renal Impairment

United States
Genzyme, a Sanofi Company

Completed

Safety, Pharmacokinetics (PK), And Hematological Activity Of AMD3100 (Plerixafor) In Subjects With Renal Impairment

Renal Impairment

United States
Vanda Pharmaceuticals

Completed

Pharmacokinetics of Tasimelteon in Subjects With Renal Impairment and Matched Control Subjects With Relatively Normal Renal Function

Renal Impairment

United States
Merck KGaA, Darmstadt, Germany

Completed

Pharmacokinetics in Subjects With Renal Impairment

Renal Impairment

Germany

3

Subscribe